Kalio

Affluent Medical : H1 2023 results. Major advances in clinical programs. Extension of cash horizon to February 2024.

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, Regulatory News Service, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Pharmaceutical industry, Medical imaging, Medical device, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • This transcatheter approach avoids an invasive "open heart" procedure and associated complications to treat mitral valve insufficiency.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

EQS-News: Affluent Medical SA: H1 2023 RESULTS - Major advances in clinical programs - Extension of cash horizon to February 2024

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Medical imaging, Medical device, Pharmaceutical industry, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • In March 2023, Affluent Medical announced the successful first implantation of the Epygon biomimetic mitral heart valve in a patient with a severe mitral valve insufficiency profile combined with several comorbidity factors.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

Affluent Medical appoints Dr. Christophe Giot Vice President Clinical Affairs.

Retrieved on: 
Monday, July 11, 2022
Trial of the century, EMEA, Acceleration, CEO, Degenerative disease, Kalio, Cardiology, Marketing, ISIN, Heart, Regulatory News Service, UCB, Company, Medicine, Actelion, AstraZeneca, Death, Bristol Myers Squibb, Sanofi, Urinary incontinence, Tricuspid valve, Patient, COMEX, Urology, Medical device, Medical imaging, Terumo, Medtech

Affluent Medical appoints Dr. Christophe Giot Vice President Clinical Affairs.

Key Points: 
  • Affluent Medical appoints Dr. Christophe Giot Vice President Clinical Affairs.
  • Affluent Medical (ISIN code: FR0013333077 - Ticker: AFME), a French medtech specialising in the international development and industrialisation of innovative medical prostheses, at a clinical stage, to treat urinary incontinence and mitral valve pathology, today announces the appointment of Dr. Christophe Giot as Vice President Clinical Affairs.
  • Michel Finance, Chairman and CEO of Affluent Medical, said: Affluent Medical is delighted to welcome Dr. Christophe Giot as we actively work on the deployment of our clinical studies with the increase in the number of patients enrolled in several centers in Europe.
  • Christophe Giot, VP Clinical Affairs, said, Affluent Medical's three devices have the potential to address large unmet medical needs.

Affluent Medical : Publication of the Universal Registration Document (URD) 2021.

Retrieved on: 
Friday, April 29, 2022
Degenerative disease, Share repurchase, AMF, Regulatory News Service, Death, XBRL, Company, Mission statement, Kalio, Heart, URD, ISIN, Trial of the century, Urinary incontinence, ESEF, Medtech

Affluent Medical : Publication of the Universal Registration Document (URD) 2021.

Key Points: 
  • Affluent Medical : Publication of the Universal Registration Document (URD) 2021.
  • An English version of the 2021 Universal Registration Document will be made available shortly.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.
  • Kalios is set to be the first medical device to be marketed in Europe.

Affluent Medical : Coverage initiation by Kepler Cheuvreux.

Retrieved on: 
Thursday, April 14, 2022
Kepler, Bird, Federal Research Public Access Act, Kepler Cheuvreux, Death, Decision-making, ISIN, Kalio, Trial of the century, Heart, Degenerative disease, China Investment Securities, Company, Urinary incontinence, Regulatory News Service, Medical imaging, Medtech

Affluent Medical : Coverage initiation by Kepler Cheuvreux.

Key Points: 
  • Affluent Medical : Coverage initiation by Kepler Cheuvreux.
  • Affluent Medical (ISIN code: FR0013333077 - Ticker: AFME), a French medtech specialising in the international development and industrialisation of innovative medical prostheses, at a clinical stage, to treat urinary incontinence and mitral valve pathology, announces today that Kepler Cheuvreux has initiated coverage of the stock.
  • Affluent Medical now benefits from Kepler Cheuvreux' coverage with the publication of a financial note entitled "Kill three birds with one stone".
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.

Affluent Medical : 2021 full-year results and update on clinical programs.

Retrieved on: 
Friday, April 1, 2022
Mitral insufficiency, Company, Recurrence, Heart, Population, EFS, Marketing, CE, Trial of the century, Death, Mortality, Incontinence, Mitral valve, Breakthrough therapy, Urinary incontinence, Program, Pathology, Woman, Hospital, Incidence, Degenerative disease, Man, Czech Republic, Voltage optimisation, Quality of life, Safety, COVID-19, Ethics, FDA, Patient, Medical imaging, Medical device, Pet, Pharmaceutical industry, Medtech, Kalio

According to Affluent Medical estimates, fewer than 4% of the 4 million patients with severe mitral insufficiency benefit from surgery.

Key Points: 
  • According to Affluent Medical estimates, fewer than 4% of the 4 million patients with severe mitral insufficiency benefit from surgery.
  • [6]
    Affluent Medical is currently developing two medical devices to address the treatment of mitral insufficiency: Kalios and Epygon.
  • Following the positive results of the Optimise study, Affluent Medical initiated a clinical study, Optimise II pivotal for its Kalios device.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.

Affluent Medical : 2022 financial communication calendar

Retrieved on: 
Monday, January 24, 2022
Calendar, Urinary incontinence, Kalio, ISIN, Death, Degenerative disease, Heart, Company, Regulatory News Service, Pathology, Mission statement, Trial of the century, Medical imaging, Medtech

Affluent Medical (ISIN code: FR0013333077 - mnemonic: AFME), a French medtech specialised in the international development and industrialisation of innovative medical prostheses - at a clinical stage - to treat urinary incontinence and the pathology of the heart mitral valve, today is announcing its 2022 financial communication calendar.

Key Points: 
  • Affluent Medical (ISIN code: FR0013333077 - mnemonic: AFME), a French medtech specialised in the international development and industrialisation of innovative medical prostheses - at a clinical stage - to treat urinary incontinence and the pathology of the heart mitral valve, today is announcing its 2022 financial communication calendar.
  • Publication of financial statements as of December 31, 2021
    Publication of financial statements as of June 30, 2022
    All communications are published after market close.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.
  • The first medical device should be marketed in Europe with Kalios.

Affluent Medical : Appointment of a new independent board member to the Affluent Medical Board of Directors.

Retrieved on: 
Wednesday, January 19, 2022
Urinary incontinence, Biomedical engineering, Patient, Kalio, Cardiology, Medtronic, Board of directors, International business, MBA, Knowledge, ISIN, Biomedicine, CEO, Emlyon Business School, Claude Bernard University Lyon 1, Industry, Marketing, Urology, Company, Hitachi, Boston Scientific, Regulatory News Service, EV3, Pathology, Biosensor, Board, Medical imaging, Management

Affluent Medical : Appointment of a new independent board member to the Affluent Medical Board of Directors.

Key Points: 
  • Affluent Medical : Appointment of a new independent board member to the Affluent Medical Board of Directors.
  • Affluent Medical (ISIN code: FR0013333077 - mnemonic: AFME), a French medtech specialised in the international development and industrialisation of innovative medical prostheses - at a clinical stage - to treat urinary incontinence and the pathology of the heart mitral valve, today announced the appointment of Soad El Ghazouani as a new independent board member to the Affluent Medical Board of Directors.
  • Soad El Ghazouani, the new member of Affluent Medical's Board of Directors, said, "Affluent Medical's two devices, Epygon and Kalios, have the potential to address broad unmet medical needs in the field of interventional cardiology.
  • Affluent Medical's Board of Directors is now composed of the following directors:

Affluent Medical : Financial results for the first half of 2021 and main clinical update.

Retrieved on: 
Wednesday, September 22, 2021
ESC, Man, Review, American College of Cardiology, Feedback, FCCP, Death, University, Icahn School of Medicine at Mount Sinai, Silver, Cotignola, Degenerative disease, University of Paris, Mitral valve, FAHA, Heart, Neuro, Group, Education, Committee, Journal, IFRS, Andreas, Cardiovascular disease, Urinary incontinence, EAU, Professor, Company, FESC, Health policy, BJU International, Kalio, Mehran, SAIME, NYHA, The Journal of Urology, Surgeon, COVID-19, Patient, FACC, FACP, American College, Ethics, Adrenal insufficiency, Nature Reviews Urology, Trial of the century, Mount Sinai Hospital, IPO, European Urology, Artus, Animal, Security (finance), Medical device, Pharmaceutical industry, Medicine

During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.

Key Points: 
  • During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.
  • On 9 June 2021, Affluent Medical announced the success of its IPO on the regulated market of Euronext Paris.
  • Starting in 2018 he broadened his field of expertise by engaging in various entrepreneurial projects before joining Affluent Medical.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.